Introduction {#S1}
============

Transient receptor potential vanilloid member 1 (TRPV1) channels are activated by both physiologically relevant and pathological stimuli, conducting large Ca^2+^ currents that initiate downstream signaling cascades ([@B7]; [@B14]; [@B25]; [@B40]). TRPV1 channels densely accumulate in nociceptor cells of dorsal root ganglia to transduce noxious sensory input into the electrochemical responses of the spinal nerve ([@B32]; [@B7], [@B6]; [@B4]). Recent evidence shows widespread TRPV1 expression in the central nervous system (CNS) tissues, including the cortex, hippocampus, hypothalamus, and retina ([@B21]; [@B29]; [@B12]; [@B30], [@B31]; [@B16]; [@B17]). TRPV1 has also been implicated in neurodegenerative disorders such as Alzheimer's disease ([@B15]; [@B2]), Parkinson's disease ([@B19]; [@B22]; [@B23]; [@B9]), Huntington's disease ([@B18]), and glaucomatous optic neuropathy, or glaucoma ([@B39]; [@B40]). Glaucoma is the leading cause of irreversible blindness ([@B26]), involving sensitivity to intraocular pressure (IOP) that stresses retinal ganglion cell (RGC) axons as they form the optic nerve ([@B5]). Many RGCs express TRPV1 channels ([@B16]; [@B17]), localizing to dendrites, unmyelinated axon segment, and cell body, where it increases with short-term elevations in IOP ([@B30], [@B31]; [@B40]) but is negligible within the optic nerve itself ([@B8]). Even so, *Trpv1^--/--^* accelerates optic nerve degeneration with elevated IOP and increases the depolarization necessary for RGCs to produce action potentials ([@B39]; [@B40]). To better understand the early stages of this acceleration, we investigated how *Trpv1^--/--^* influences physiological signaling along the optic nerve with short-term elevations in IOP. We found that enhanced excitability in *Trpv1^--/--^* optic nerve was associated with longer axonal nodes of Ranvier with greater levels of the voltage-gated sodium channel, NaV1.6. These results suggest a role for TRPV1 in native tissue to regulate NaV in response to disease-relevant stressors. The absence of this tuning in *Trpv1^--/--^* mice suggests that accelerated axonopathy could arise from excessive excitation even as elevated IOP stresses match available metabolic resources in the optic projection to the brain ([@B3]; [@B5]).

Materials and Methods {#S2}
=====================

Animal Experiments {#S2.SS1}
------------------

Adult male *Trpv1^--/--^* (B6.129 × 1-Trpv1^TM\ 1Jul^/J) mice (1.5--2 months old) were obtained from The Jackson Laboratory, whereas the appropriate wild-type (WT) background strain C57Bl/6 mice were purchased from Charles River Laboratories (male, 1.5--2 months old). The *Trpv1^--/--^* mice have a targeted mutation causing a non-functional truncated form of TRPV1 ([@B6]; [@B27]; [@B35]). *Trpv1^--/--^* animals were genotyped prior to performing experiments, following our protocol ([@B39]; [@B40]; [@B31]) using primers recommended by the vendor. The mutant forward primer was TAA AGC GCA TGC TCC AGA CT compared with the WT forward primer of TGG CTC ATA TTT GCC TTC AG. The common primer was CAG CCC TAG GAG TTG ATG GA. DNA gel electrophoresis of *Trpv1^--/--^* animals showed a single band at 176 bp, indicative of truncated TRPV1 ([@B6]; [@B27]; [@B35]), whereas WT showed a single band at 289 bp indicative of the native protein. We verified this pattern in each animal utilized.

Mice were maintained in a 12 h light/dark cycles, and animals were allowed water and standard rodent chow as desired. All animal experiments were approved by The Vanderbilt University Medical Center Institutional Animal Care and Use Committee. Baseline IOP was measured bilaterally in anesthetized (2.5% isoflurane) mice using Tono-Pen XL (Medtronic Solan) for 1--2 days prior to experimental manipulation. Baseline IOP measurements were averaged (day 0). After baseline IOP measurements, unilateral elevation of IOP was induced by injecting 1.5 μl of 15 μm polystyrene microbeads (Invitrogen) into the anterior chamber; the fellow eye received an equal volume of sterile saline to serve as control. We measured IOP 2--3 times per week for 2 weeks as described previously ([@B11]; [@B40]; [@B28]).

Optic Nerve Compound Action Potential Electrophysiology {#S2.SS2}
-------------------------------------------------------

Animals were euthanized by cervical dislocation and decapitated. The skull was cut along the sagittal suture and removed, and the optic nerves were sectioned from the brain. Optic nerves were cut at the optic chiasm and posterior to the optic nerve head, and nerves were placed in carbogen-saturated (95% O~2~, 5% CO~2~) ice-cold (4°C) artificial cerebrospinal fluid (aCSF) for 30 min ([@B38]). The aCSF contained (in mM/L) 124 NaCl, 3 KCl, 2 CaCl~2~, 2 MgCl~2~, 1.25 NaH~2~PO~4~, 23 NaHCO~3~, and 10 glucose ([@B3]). The pH of the aCSF was 7.4.

Optic nerves were incubated in ice-cold aCSF to slow metabolism because we recorded from optic nerves one at a time. The first nerve recorded from (saline- or microbead-injected eyes) was alternated daily to avoid any possible order effects. After incubation, one optic nerve was transferred into a physiological chamber (Model PH1, Warner Instruments) and continually perfused at a rate of 2 mL/min using a peristaltic pump (Model 7518, Masterflex) and maintained at 35°C (Model TC-344C, Warner Instruments). Optic nerves adjusted to physiological conditions for 30 min prior to recording. After adjustment to physiological conditions, the rostral end of the optic nerve was positioned into a bipolar recording suction electrode (Model 573040, A-M Systems), and the caudal end of the optic nerve was positioned into a custom-made bipolar stimulating suction electrode. The syringe section of each electrode was attached to separate micromanipulators (Model MM33, WPI) to allow fine positioning of the electrodes. The electrode section of the suction electrodes was fabricated from borosilicate glass (Model TW150-4, WPI) that was heat-pulled (Model P2000, Sutter Instruments) to form an average opening of ∼350 μm in diameter. The stimulating electrode contained a Ag wire, and the recording pipette contained a Ag/AgCl wire; both pipettes were filled with aCSF.

Evoked potentials were bandpass filtered (0.0001--10 kHz), amplified (100 × gain, DAM-60, WPI), digitized (Digidata 1440A, Molecular Devices), and sampled at 50 kHz (Clampex 10.6, Molecular Devices). Afterward, we measured the resistance between the nerve and recording pipette by stimulating the nerve with 10-μs 100-μA pulses at a minimum of three positions along the optic nerve and measuring the compound action potential (CAP) (Model ISO-STIM 01-DPI, NPI). The resistance of the optic nerve and pipette at each spatial position along the nerve was computed using Ohm's law.

Current-evoked CAPs were obtained for at least three spatial positions along each optic nerve. Thus, at each spatial position, the resistance between the recording pipette and nerve was unique. We then plotted the resultant CAP area obtained at each spatial position as a function of resistance. Then, we obtained the slope of the linear regression of these data. The slope of the data represents an approximation of the current-induced voltage output of the nerve ([@B36]).

In a subset of experiments, CAPs were evoked with brief, 10 μs, square pulses, ranging from 10 to 200 V, every 30 s until a maximal response was produced. Maximal response was defined by the peak of the CAP. Once we determined the voltage required to produce a maximum response, we challenged optic nerve excitability by bath application of 300 and 600 nM of 4,9-anhydrotetrodotoxin (aTTX; Alomone Labs) or 100 nM of iodoresiniferatoxin (IRTX; Tocris). After 5 min of drug application, an evoked CAP was obtained using the max-response stimulus previously determined under normal bath conditions. To assess excitability within the optic nerve, we computed the percent decrease or percent of baseline of the evoked CAP based on before and after drug responses.

At the end of each recording session, optic nerves were placed in 4% paraformaldehyde overnight at −4°C. Afterward, we placed nerves on slides, imaged nerves on a microscope slide micrometer, and quantified length and width using the "segmented line" tool in ImageJ \[Version 1.51i, National Institutes of Health (NIH)\]. The average optic nerve width for WT and *Trpv1^--/--^* mice was 0.329 ± 0.004 and 0.333 ± 0.003 mm, respectively. There was no difference in optic nerve length between genotypes (*p* = 0.45) or between experimental condition (*p* = 0.56).

Optic Nerve Immunohistochemistry, Imaging, and Analysis {#S2.SS3}
-------------------------------------------------------

For optic nerve sections, mice were first perfused with phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. Optic nerves were placed separately into optimal cutting temperature (OCT) compound (Fisher Scientific). Optic nerves were sectioned longitudinally every 7 μm, taking care to keep the nerves as flat as possible. Sections were first blocked with 5% normal donkey serum for 2 h and then incubated in primary antibodies for 3 days at 4°C with gentle shaking. Primary antibodies used for optic nerve sections were mouse-contactin-associated protein 1 (Caspr1, 1:300, Millipore) and rabbit-NaV1.6 (1:200, Alomone). Confocal micrographs of all sections were acquired using an Olympus FV1000 inverted microscope with 100 × objective and 2 × zoom.

Optic nerve node--paranode complexes were assessed using similar methods as [@B1]. To determine the length of the node and paranode segments for each node--paranode complex, the following analysis was performed for each complex using a series of custom-written MATLAB functions: First, the most prominent trough of the Caspr1 staining intensity profile was noted, and the location of its minimum point identified. Next, the most prominent peak to both the right and left of this minimum point was identified. These maxima were averaged, and half of the average value was used to define a threshold intensity value to distinguish node and paranode segments. For each of the two identified peaks, the contiguous region surrounding the peak and above the threshold was considered paranode, whereas the region between the two paranode segments and under the threshold was considered node. The length of these segments and their average staining intensity (Caspr1 for paranode and NaV1.6 for node) were calculated.

All data are presented as mean ± SEM. Graphs were made using Sigma Plot Version 14 (Systat, San Jose, CA, United States). Statistical analyses were performed using Sigma Plot and Matlab (R2019a, Natick, MA, United States). Parametric statistics were performed (*t*-tests, ANOVAs) if data passed normality and equal variance tests; otherwise, we performed non-parametric statistics (Mann--Whitney, ANOVA on ranks).

Results {#S3}
=======

*Trpv1^--/--^* Following Short-Term Intraocular Pressure Elevation Increases Optic Nerve Excitability {#S3.SS1}
-----------------------------------------------------------------------------------------------------

Following our protocol for conformational genotyping ([@B39]; [@B40]; [@B31]), *Trpv1^--/--^* mice showed a single product band at 176 bp, indicative of a non-functional truncated form of *Trpv1* ([@B6]; [@B27]; [@B35]), whereas WT C57 mice had a prominent band at 289 bp characteristic of the native protein ([Figure 1A](#F1){ref-type="fig"}).

![**(A)** Genotype confirmation shows the band for wild-type (WT) *Trpv1* at 289 bp (lane 1, C57 background strain) vs. the 176 bp mutant *Trpv1* (lanes 2 and 3). **(B)** Intraocular pressure (IOP) for WT and *Trpv1^--/--^* mice following unilateral injection of microbeads (vs. saline injection control, Ctrl) was similar between genotypes. **(C)** IOP significantly increased in WT (33%) and *Trpv1^--/--^* (29%) eyes compared with their respective saline-injected control eyes (WT: \**p* \< 0.01, *Trpv1^--/--^*: \**p* \< 0.01). Statistics: Independent samples *t*-tests. *n* = 16 (WT Ctrl), 16 (WT 2Wk), 15 (*Trpv1^--/--^* Ctrl), and 15 (*Trpv1^--/--^* 2Wk).](fphys-11-00249-g001){#F1}

Recently, we discovered that short-term (2 weeks) elevations in IOP enhance excitability in multiple types of RGCs and their axons ([@B28]). Following the same procedure for unilateral microbead injection, IOP significantly increased for the 2-week duration of the experiment for both WT and *Trpv1^--/--^* mice ([Figure 1B](#F1){ref-type="fig"}). In WT mice, IOP increased by 33% (20.5 ± 1.3 mmHg) compared with saline-injected eyes (15.4 ± 1.1 mmHg, ^∗^*p* \< 0.01). Similarly, in *Trpv1^--/--^* mice, IOP increased by 29% in microbead-injected eyes (19.6 ± 1.1 mmHg) relative to saline controls (15.2 ± 1.0 mmHg, *p* \< 0.01, [Figure 1C](#F1){ref-type="fig"}). Genotype had no influence on IOP for either saline- or microbead-injected eyes (*p* ≥ 0.96).

To determine whether IOP modulates electrical activity in the myelinated optic nerve as it does for the retina, we measured the current-evoked CAP ([@B3]). Optic nerve CAP typically demonstrated a single voltage peak following depolarizing current stimulation ([Figure 2A](#F2){ref-type="fig"}), which could be eliminated by blocking voltage-gated sodium channels with tetrodotoxin (TTX; 1 μM; [Figure 2B](#F2){ref-type="fig"}). In the retina, RGC excitability can be modulated directly by TRPV1 activation and inhibition ([@B40]). This is not so for optic nerve. Application of the TRPV1-specific antagonist IRTX at sub-micromolar concentrations known to inhibit TRPV1 ([@B37]) did not significantly affect the evoked CAP for naïve WT optic nerve (*p* = 0.91, [Figure 2C](#F2){ref-type="fig"}).

![**(A)** Compound action potential (CAP) area measured as integral (vertical gray lines) above baseline (dashed line) for current-evoked voltage changes over time. **(B)** Example of CAP from wild-type (WT) naïve optic nerve in artificial cerebral spinal fluid (aCSF) and with 1 μM of tetrodotoxin (TTX) added, which eliminated the CAP. **(C)** Example CAP from WT naïve optic nerve before and after bath application of 100 nM of iodoresiniferatoxin (IRTX) (left), which did not influence area when normalized to aCSF (*p* = 0.34, *n* = 5). **(D)** Integrated CAP calculated as in **(A)** increases with nerve resistance for individual WT (*n* = 7) and *Trpv1^--/--^* (*n* = 5) nerves from control eyes. Slope of best-fitting regression line indicates CAP voltage (right), which did not differ between WT, *Trpv1^--/--^*, and WT naïve (*n* = 4; *p* = 0.62). Latency too did not differ (*p* = 0.40). **(E)** Integrated CAP for individual WT (*n* = 7) and *Trpv1^--/--^* (*n* = 5) nerves following 2 weeks of elevated IOP (left). For *Trpv1^--/--^* nerves, elevated IOP increased slope of best-fitting line compared with that of corresponding control (CAP voltage, right; \**p* = 0.001). Latency did not differ for either WT or *Trpv1^--/--^* nerves compared with control nerves (*p* = 0.59). Statistics: **(C,E)** independent samples *t*-tests; **(D)** one-way ANOVA.](fphys-11-00249-g002){#F2}

Resistance to stimulating current varies with axon density and diameter, extra-axonal space and glia, and positioning of the recording electrode, all of which alter the measured response ([@B36]). To compare optic nerve CAP between animals more accurately, we obtained multiple measurements while varying the positioning of the recording electrode. As resistance increased, so too did the integral of the CAP response ([Figures 2D,E](#F2){ref-type="fig"}), with the slope of the best-fitting line yielding a more precise measure of CAP voltage ([@B36]). In addition, we assessed the amount of time required for axons to conduct action potentials by measuring the response latency as the time from stimulus onset to peak of the CAP. For control nerves, *Trpv1^--/--^* did not influence the CAP voltage (*p* = 0.16) or latency (*p* = 0.40) as compared with WT ([Figure 2D](#F2){ref-type="fig"}). In contrast, following 2 weeks of elevated IOP, *Trpv1^--/--^* significantly increased the CAP voltage relative to control nerves (6.3 ± 0.4 vs. 4.2 ± 0.3 mV; *p* = 0.001) but did not modulate latency. Elevated IOP did not affect the WT CAP voltage or latency as compared with control nerves ([Figure 2E](#F2){ref-type="fig"}).

*Trpv1^--/--^* Optic Nerve Is Less Sensitive to NaV1.6 Antagonism {#S3.SS2}
-----------------------------------------------------------------

Action potentials are propagated in myelinated nerve by activation of the voltage-gated sodium (NaV) channel 1.6, which densely accumulates within nodes of Ranvier ([@B10]). Because IRTX did not significantly modulate optic nerve CAP ([Figure 2C](#F2){ref-type="fig"}), we tested whether the increase in *Trpv1^--/--^* optic nerve CAP with elevated IOP ([Figure 2E](#F2){ref-type="fig"}) is due to NaV1.6 activity. We again measured optic nerve CAP following bath application of 300 and 600 nM of aTTX, a selective inhibitor of the NaV1.6 subunit ([@B13]). For WT optic nerve, the CAP was suppressed by 300 nM and further reduced by 600 nM of aTTX ([Figure 3A](#F3){ref-type="fig"}). In contrast, the *Trpv1^--/--^* optic nerve CAP appeared relatively insensitive to aTTX of either concentration ([Figure 3B](#F3){ref-type="fig"}). We quantified the influence of aTTX as the percent decrease in CAP area following drug administration, normalized to baseline area for each nerve. In WT nerve, regardless of IOP elevation or aTTX concentration, CAP area declined significantly with time after drug application ([Figure 3C](#F3){ref-type="fig"}), as indicated by the slope of the best-fitting regression line. The CAP for WT control nerves decreased by 50% following 300 nM of aTTX and by 91% following 600 nM of aTTX compared with baseline ([Figure 3D](#F3){ref-type="fig"}). Elevated IOP had little influence for either aTTX concentration, as compared with control nerves (*p* ≥ 0.53). For *Trpv1^--/--^*, aTTX had little influence on CAP over time, with the slope of the best-fitting regression line significantly declining only for 600 nM of aTTX treatment of control nerves ([Figure 3E](#F3){ref-type="fig"}). With 300 nM, only the CAP for 2-week nerves declined compared with baseline, whereas only control nerves declined further with 600 nM compared with treatment with 300 nM ([Figure 3F](#F3){ref-type="fig"}).

![**(A,B)** Example compound action potential (CAP) responses of nerves from Ctrl eyes and following 2 weeks of elevated intraocular pressure (IOP) from wild-type (WT) and *Trpv1^--/--^* mice with bath application of 300 and 600 nM of aTTX. **(C)** Mean WT CAP area for control and 2-week nerves decreases over time following bath application of 300 and 600 nM of aTTX. Individual recordings normalized to corresponding baseline (pre-drug) response. Slopes of best-fitting regression lines indicated significant decline (*p*-values indicated). **(D)** Final CAP area for WT decreases significantly following 300 nM of aTTX for both control (*n* = 7, 50% decrease) and 2-week (*n* = 6, 59% decrease) nerves compared with baseline for each (^\#^*p* ≤ 0.03). CAP area decreased further from baseline for control (*n* = 6, 91% decrease) and 2-week nerves (*n* = 6, 83% decrease) following application of 600 nM of aTTX, both significant declines compared with 300 nM (\**p* \< 0.001). **(E)** Mean *Trpv1^--/--^* CAP area following bath application of 300 and 600 nM of aTTX; for slopes of best-fitting regression lines, only control nerves with 600 nM of aTTX showed significant decline (*p*-values indicated). **(F)** Final CAP area for *Trpv1^--/--^* control nerves were minimally affected by 300 nM of aTTX (*n* = 5, 0.5% decrease), whereas area for 2-week nerves declined compared with baseline (*n* = 5, 18% decrease; ^\#^*p* = 0.02). Like WT, 600 nM of aTTX caused a greater reduction in CAP area compared with 300 nM for Ctrl nerves (35% decrease; \**p* = 0.02). Statistics: **(C,E)** linear regressions; **(D,F)**: one-way ANOVAs, Tukey *post-hoc*.](fphys-11-00249-g003){#F3}

*Trpv1^--/--^* Alters NaV1.6 Density and Node Length With Elevated Intraocular Pressure {#S3.SS3}
---------------------------------------------------------------------------------------

The results in [Figure 3](#F3){ref-type="fig"} indicate that *Trpv1^--/--^* optic nerve is relatively insensitive to aTTX suppression of NaV1.6 activation than are WT nerves. In the myelinated optic nerve, NaV1.6 localizes to nodes of Ranvier flanked by paranodes defined by the membrane protein Caspr1 (contactin associated protein 1; [@B10]). Immunolabeling for NaV1.6 and Caspr1 in longitudinal sections confirmed this fundamental configuration in both WT and *Trpv1^--/--^* optic nerves ([Figure 4](#F4){ref-type="fig"}). Compared with WT nerves from control and IOP-stressed eyes ([Figures 4A,B](#F4){ref-type="fig"}), the node--paranode complex appeared smaller in *Trpv1^--/--^* optic nerves with more intense location of NaV1.6 ([Figures 4C,D](#F4){ref-type="fig"}).

![**(A--D)** Representative confocal micrographs of Caspr1 (green) and NaV1.6 (red) immunostaining of longitudinal optic nerve sections from wild-type (WT) **(A,B)** and *Trpv1^--/--^* **(C,D)** mice. Scale bar = 10 μm.](fphys-11-00249-g004){#F4}

To quantify these apparent differences, we measured paranode and node length and intensity of Caspr1 and NaV1.6 localization within well-defined paranode--node complexes ([Figure 5A](#F5){ref-type="fig"}). For WT optic nerve, elevated IOP had no effect on levels of paranodal Caspr1 compared with control (*p* = 0.76) nor on paranode length (*p* = 0.81; [Figure 5B](#F5){ref-type="fig"}). However, for *Trpv1^--/--^* optic nerve, elevated IOP increased Caspr1 significantly compared with that for WT (*p* = 0.012; [Figure 5B](#F5){ref-type="fig"}, left) whereas significantly shortening paranode length compared with that for WT (*p* \< 0.001; [Figure 5B](#F5){ref-type="fig"}, right). Within the nodes themselves, NaV1.6 was significantly higher for *Trpv1^--/--^* compared with WT for both control and 2-week nerves (*p* \< 0.001; [Figure 5C](#F5){ref-type="fig"}, left). As with Caspr1-labeled paranodes, *Trpv1^--/--^* significantly shortened the nodes compared with WT (*p* \< 0.001; [Figure 5C](#F5){ref-type="fig"}, right). Thus, NaV1.6 concentrates at a higher level in truncated paranode--node complexes in *Trpv1^--/--^* optic nerve. We found significant positive correlations between node and paranode length in WT control and 2-week nerves (*p* \< 0.001, [Figure 5D](#F5){ref-type="fig"}, left). For *Trpv1^--/--^* optic nerve, there was no correlation (Ctrl, *p* = 0.62; 2Wk, *p* = 0.09, [Figure 5D](#F5){ref-type="fig"}, right). For both WT and *Trpv1^--/--^* control nerves, NaV1.6 intensity decreased significantly with increasing nodal length, so that NaV1.6 was more concentrated in shorter nodes (*p* ≤ 0.03, [Figure 5E](#F5){ref-type="fig"}). However, for *Trpv1^--/--^* nerves with elevated IOP, the relationship was reversed so that NaV1.6 concentrated in *longer* nodes (*p* = 0.05, [Figure 5E](#F5){ref-type="fig"}, right); this was not so for WT nerves (*p* = 0.07). These results suggest that the combined increase in NaV1.6 localization with decreased length of the paranodal complex strengthens the *Trpv1^--/--^* CAP, rendering these nerves far less sensitive to aTTX antagonism ([Figure 3](#F3){ref-type="fig"}). That elevated IOP increases NaV1.6 with increasing node length likely explains the increased CAP for *Trpv1^--/--^* nerves under these conditions.

![**(A)** High magnification confocal micrographs of longitudinal sections through Ctrl and 2 Wk wild-type (WT) and *Trpv1^--/--^* optic nerves show Caspr1-labeled paranodes (green) flanking NaV1.6 (red) within nodes of Ranvier. **(B)** *Trpv1^--/--^* 2 Wk paranodes contain increased Caspr1 than did WT 2 Wk nerves (left, \**p* = 0.012) and are shorter (right, \**p* \< 0.001). **(C)** NaV1.6 is higher in nodes of Ranvier of *Trpv1^--/--^* nerves (left) compared with WT Ctrl (^\#^*p* \< 0.001) and 2 Wk (\**p* \< 0.001) optic nerve (left), although node length is significantly shorter for both *Trpv1^--/--^* Ctrl (^\#^*p* \< 0.001) and 2 Wk (\**p* \< 0.001) nerves. Elevated intraocular pressure (IOP) had no effect on either measure (*p* ≥ 0.88). **(D)** There is a positive relationship between node and paranode lengths in WT optic nerves (left), however, this relationship is lost in *Trpv1^--/--^* (right) optic nerves. Elevated IOP had no effect on this relationship for WT or *Trpv1^--/--^* optic nerves. **(E)** NaV1.6 intensity decreases as node length increases in WT (left) and *Trpv1^--/--^* (right) control optic nerves. Following IOP elevation, this relationship is lost in WT nerves, whereas the relationship becomes positive in *Trpv1^--/--^* nerves. Scale = 5 μm **(A)**. Statistics: **(B,C)**: one-way ANOVAs, Tukey *post-hoc*; **(D,E)** linear regressions. Total nodes analyzed: WT Ctrl, 3,942; WT 2 Wk, 3,890; *Trpv1^--/--^* Ctrl, 2,024; *Trpv1^--/--^* 2 Wk, 2,191. Five animals per condition. Ten images per animal.](fphys-11-00249-g005){#F5}

Discussion {#S4}
==========

Previously, we found that *Trpv1^--/--^* accelerates optic nerve axonopathy with elevated IOP, reducing nerve area, axon density, and axon transport to the brain ([@B39]). The deleterious influence of *Trpv1^--/--^* on nerve health and axon function with IOP-related stress likely can be linked to cationic activity. Here, we sought to determine the impact of *Trpv1^--/--^* with short-term IOP elevation on optic nerve signaling to the brain, using the evoked CAP. As expected ([@B3]), the optic nerve CAP demonstrated a single-peaked voltage inflection in response to depolarizing current that was eliminated by application of the voltage-gated sodium channel antagonist, TTX ([Figures 2A,B](#F2){ref-type="fig"}), underscoring the dependence of CAP on these channels. Under control conditions, in the absence of IOP-related stress, the CAP for WT and *Trpv1^--/--^* optic nerves was identical, and naïve CAP was unaffected by specific pharmacological antagonism of TRPV1 ([Figures 2C,D](#F2){ref-type="fig"}).

Our key physiological result is that modest, short-term IOP elevation significantly increases *Trpv1^--/--^* optic nerve CAP. On the surface, this finding is paradoxical. We have recently shown TRPV1 expression and RGC excitability concurrently increase following 2 weeks of elevated IOP ([@B40]). In that study, *Trpv1^--/--^* eliminated the stress-related enhancement of RGC excitability, and *Trpv1^--/--^* RGCs required larger depolarizing currents to generate action potentials with elevated IOP. On the basis of this collective evidence, one would expect IOP elevation to reduce *Trpv1^--/--^* optic nerve CAPs. How then do we explain our results? *Trpv1^--/--^* nerves were relatively impervious to NaV1.6 antagonism by aTTX, which suppressed the WT CAP ([Figure 3](#F3){ref-type="fig"}). This difference accompanies shorter nodes of Ranvier with far greater NaV1.6 localization in *Trpv1^--/--^* but not WT nerves ([Figures 4](#F4){ref-type="fig"}, [5](#F5){ref-type="fig"}). In fact, NaV1.6 in WT optic nerve nodes is unaltered following up to 5 weeks of microbead-induced IOP elevation ([@B33]). This novel finding suggests that TRPV1, which is typically associated with presynaptic potentiation of glutamatergic action ([@B19]; [@B20]), can also tune channel expression within axons -- even though localization of TRPV1 in the optic nerve head is negligible ([@B8]).

Our data show that *Trpv1^--/--^* causes a compensatory aggregation of NaV1.6 protein expression within nodes of Ranvier and a significant decrease in nodal length ([Figure 5C](#F5){ref-type="fig"}). This may serve as a cautionary note that genetic excision of a single gene, *Trpv1* in this case, can lead to unexpected effects on neuronal structure and expression levels of other channels. Here, we observed that *Trpv1^--/--^* led to increased NaV1.6 expression, which conferred greater resistance to the NaV1.6 antagonist, aTTX ([Figure 3](#F3){ref-type="fig"}). The general observation that overexpression of a drug target correlates with a higher resistance to inhibition is a fundamental assumption for drug target identification. This assumption is often true when inhibition of the target only reduces target activity. However, if inhibition of the target also catalyzes harmful downstream effects, drug efficacy cannot be predicted ([@B24]). Although it is unknown if inhibition of NaV1.6 by aTTX impacts off-target sites, here, we find that for WT control nerves, 300 nM of aTTX caused a 50% reduction of the CAP and 600 nM of aTTX decreased the CAP near 100%, suggesting that NaV1.6 resistance to aTTX is linear ([Figures 3D,F](#F3){ref-type="fig"}).

Finally, we found that *Trpv1^--/--^* with elevated IOP causes a modest but significant shift in the relationship between NaV1.6 expression and node length, where NaV1.6 accumulates more in longer nodes ([Figure 5E](#F5){ref-type="fig"}). Interestingly, others have found that increased nodal length and ectopic expression of NaV1.6 in aged optic nerves are related to larger CAP despite decreased levels of ATP ([@B34]). We previously found that elevated IOP in *Trpv1^--/--^* mice accelerates ATP-dependent anterograde axon transport deficits and optic nerve axon degeneration ([@B39]). Ultimately, our results indicate that IOP-related stress, like aging, requires a redistribution of energy resources at the expense of axon transport to preserve voltage-dependent axon signaling. In the absence of TRPV1, this demand is increased, further taxing a vulnerable system. Thus, in glaucoma and other age-related neurodegenerative diseases, TRPV1 may reconfigure NaV expression in neurons under stress to normalize excitability to existing metabolic resources.
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